Главная › Множественная миелома › Северная Каролина › Durham
Клинические исследования Множественная миелома в городе Durham, NC
37 исследований по теме Множественная миелома ищут участников в центрах в городе Durham и поблизости (в радиусе около 30 миль). Откройте исследование, чтобы узнать критерии участия и контакты исследовательской группы.
Официальный текст исследования (на английском)
Ищете участников для исследования? Разместите его вверху страницы — $99 на 30 дней →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Набор участниковФаза 3
- Research Site, Chapel Hill · 10 миль отсюда
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Набор участниковФаза 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 миль отсюда
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Набор участниковФаза 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Набор участниковФаза 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 миль отсюда
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Набор участниковФаза 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 миль отсюда
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Набор участниковФаза 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 2
- University of North Carolina Medical Center, Chapel Hill · 10 миль отсюда
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Набор участниковФаза 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 миль отсюда
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Набор участниковФаза 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 миль отсюда
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Набор участниковФаза 1/2
- GSK Investigational Site, Chapel Hill · 10 миль отсюда
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Набор участниковФаза 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Набор участниковФаза 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Набор участниковФаза 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 миль отсюда
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Набор участников
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 миль отсюда
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Набор участниковФаза 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Набор участниковФаза 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 миль отсюда
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Набор участниковФаза 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 миль отсюда
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Набор участниковФаза 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 миль отсюда
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Набор участниковФаза 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 миль отсюда
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Набор участниковФаза 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 миль отсюда
Registry of Older Patients With Cancer
Набор участниковНаблюдательное исследование
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 миль отсюда
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Набор участниковФаза 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Набор участниковФаза 2
- University of North Carolina, Chapel Hill · 10 миль отсюда
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Набор участниковФаза 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 миль отсюда
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Набор участниковФаза 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 миль отсюда
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Набор участниковФаза 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набор участниковФаза 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 миль отсюда
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Набор участниковФаза 1
- University of North Carolina, Chapel Hill · 10 миль отсюда
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Набор участниковФаза 1
- University of North Carolina, Chapel Hill · 10 миль отсюда
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Набор участниковФаза 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 миль отсюда
Registry for Adults With Plasma Cell Disorders (PCD's)
Набор участниковНаблюдательное исследование
- North Carolina Cancer Hospital, Chapel Hill · 10 миль отсюда
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Набор участниковНаблюдательное исследование
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 миль отсюда
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Набор участниковФаза 1
- Duke University Health System (DUHS), Durham
Исследования Множественная миелома в других городах
- New York City, NY60 исследований
- Boston, MA42 исследований
- Atlanta, GA41 исследование
- Houston, TX38 исследований
- Nashville, TN32 исследований
- Denver, CO27 исследований
- Rochester, MN24 исследований
- St. Louis, MO24 исследований
- Columbus, OH24 исследований
- Baldwin Park, CA23 исследований
- Chicago, IL22 исследований
- Seattle, WA22 исследований
Другие исследования в городе Durham
- Рак молочной железы63 исследований
- Рак (все виды)58 исследований
- Немелкоклеточный рак легкого39 исследований
- Метастатический рак33 исследований
- Острый миелоидный лейкоз33 исследований
- Рак легких32 исследований
- Рак простаты32 исследований
- Колоректальный рак28 исследований
- Хронический лимфоцитарный лейкоз27 исследований
- Рак яичников27 исследований
- Сердечная недостаточность26 исследований
- Рак поджелудочной железы24 исследований
Источник: ClinicalTrials.gov, данные получены 5 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.